Summary | Shares of Valeant Pharmaceuticals fell more than 40%
after the drugmaker slashed its guidance, announced unaudited
fourth-quarter results that were below expectations and warned
it could be in danger of defaulting on some of its debt if it
doesn't file an already delayed annual report by an April
deadline. ...
blogs.wsj.com | 15 March 2016